Insulin-like Growth Factor I Synergizes with Interleukin 4 for Hematopoietic Cell Proliferation Independent of Insulin Receptor Substrate Expression
Overview
Affiliations
In the present study, we investigated the potential role of insulin-like growth factor I (IGF-I) receptor (IGF-IR) in cell proliferation by overexpressing it in 32D myeloid progenitor cells. The overexpression of IGF-IR caused the transfectants to proliferate in response to IGF-I in the absence of insulin receptor substrate (IRS) expression. The activation of overexpressed wild-type IGF-IR, but not that of an ATP-binding mutant of IGF-IR, resulted in the increased tyrosine phosphorylation of several intracellular proteins, including SHC, Src homology 2-containing inositol-5-phosphatase, protein kinase C-delta, and Erk2. Grb2 association with SHC and mitogen-activated protein kinase (MAPK) activity was also enhanced in response to IGF-I stimulation. Interestingly, the stimulation of the IGF-IR transfectants with interleukin 4 (IL-4) also resulted in strong mitogenesis independent of IRS expression. Moreover, IGF-I and/or IL-4 induced long-term cell growth of the IGF-IR transfectants. IL-4 was able to synergize with IGF-I for DNA synthesis, even in the parental 32D cells and a pro-B-cell line, Baf3, indicating the physiological importance of the two growth factors in hematopoietic cell proliferation. IL-4 stimulation of the IGF-IR transfectants resulted in enhanced tyrosine phosphorylation of SHC, Erk2, and signal transducer and activator of transcription 6 (STAT6) proteins. Both IL-4 and IGF-I were able to induce c-myc early response gene expression, and this expression was maximal in the presence of both factors. Finally, we demonstrated that a MAPK kinase inhibitor was able to suppress mitogenesis of the IGF-IR transfectants in response to IGF-I and/or IL-4. Together, our results suggest that IL-4 synergizes with IGF-I for hematopoietic cell proliferation, likely through cross talk between SHC/Grb2/MAPK and STAT6 pathways and through c-myc gene up-regulation.
Reis L, Ramos-Sanchez E, Araujo F, Leal A, Ozaki C, Sevillano O J Immunol Res. 2021; 2021:6614475.
PMID: 34036108 PMC: 8116165. DOI: 10.1155/2021/6614475.
Oherle K, Acker E, Bonfield M, Wang T, Gray J, Lang I Immunity. 2020; 52(2):275-294.e9.
PMID: 32075728 PMC: 7382307. DOI: 10.1016/j.immuni.2020.01.005.
Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis.
Machado-Neto J, Fenerich B, Rodrigues Alves A, Fernandes J, Scopim-Ribeiro R, Coelho-Silva J Clinics (Sao Paulo). 2018; 73(suppl 1):e566s.
PMID: 30328953 PMC: 6169455. DOI: 10.6061/clinics/2018/e566s.
Reis L, Ramos-Sanchez E, Petitto-Assis F, Nerland A, Hernandez-Valladares M, Selheim F Mediators Inflamm. 2018; 2018:9787128.
PMID: 30150896 PMC: 6087592. DOI: 10.1155/2018/9787128.
Motallebnezhad M, Aghebati-Maleki L, Jadidi-Niaragh F, Nickho H, Samadi-Kafil H, Shamsasenjan K Tumour Biol. 2016; 37(9):11711-11721.
PMID: 27444280 DOI: 10.1007/s13277-016-5176-x.